Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404–15

Autor:	Nirmish Singla
Rok vydání:	2020
Předmět:	medicine.medical_specialty Bevacizumab business.industry Sunitinib Urology medicine.disease law.invention Randomized controlled trial Atezolizumab law Renal cell carcinoma Medicine In patient Open label business medicine.drug
Zdroj:	European Urology. 77:e168-e169
ISSN:	0302-2838
DOI:	10.1016/j.eururo.2019.09.015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::25331705502d27af75c58dbeed79b653 https://doi.org/10.1016/j.eururo.2019.09.015 Zobrazit plný text záznamu Full Text from ScienceDirect